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miRNAsThe heart is a very complex conglomeration of organized interactions between various different cell types that all
aid in facilitating myocardial function through contractility, sufﬁcient perfusion, and cell-to-cell reception. In
order to make sure that all features of the heart work effectively, it is imperative to have a well-controlled com-
munication system among the different types of cells. One of the most important ways that the heart regulates
itself is by the use of extracellular vesicles, more speciﬁcally, exosomes. Exosomes are types of nano-vesicles, nat-
urally released from living cells. They are believed to play a critical role in intercellular communication through
themeans of certain mechanisms including direct cell-to-cell contact, long-range signals as well as electrical and
extracellular chemical molecules. Exosomes containmany unique features like surface proteins/receptors, lipids,
mRNAs, microRNAs, transcription factors and other proteins. Recent studies indicate that the exosomal contents
are highly regulated by various stress and disease conditions, in turn reﬂective of the parent cell status. At pres-
ent, exosomes are well appreciated to be involved in the process of tumor and infection disease. However, the
research on cardiac exosomes is just emerging. In this review, we summarize recent ﬁndings on the pathologic
effects of exosomes on cardiac remodeling under stress and disease conditions, including cardiac hypertrophy,
peripartum cardiomyopathy, diabetic cardiomyopathy and sepsis-induced cardiovascular dysfunction. In addi-
tion, the cardio-protective effects of stress-preconditioned exosomes and stem cell-derived exosomes are also
summarized. Finally, we discuss how to epigenetically reprogram exosome contents in host cells which makes
them beneﬁcial for the heart.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Cardiovascular disease is the number one cause of death in human
beings,with approximately one in every four deaths being cardiac relat-
ed [1]. The mammalian heart is thought of as a highly stressed organ
which continually keeps beating and outputs blood/nutrition to the
whole body. To maintain effective myocardial function, synchronized
communication among different cell types within the heart is needed.
It is estimated that the human heart contains two to three billion
cardiomyocytes, which account for approximately one-third of the
total number of cells in the heart [2]. This balance includes a wide
array of additional cell types, such as smooth muscle cells, endothelial
cells, ﬁbroblasts, mast cells, immune system-related cells, other connec-
tive tissue cells and pluripotent cardiac stem cells [2–4]. It is becoming
clear that a number of local and long-distance cell–cell communications
contribute to themaintenance of normal cardiac homeostasis as well as
responses to hypertrophic stimuli [4–12]. These include growth factor-acology and Cell Biophysics,
rt Sabin Way, Cincinnati, OHmediated paracrine/autocrine and adiponectin-mediated endocrine sig-
nals, gap junction-mediated cell–cell contacts, and cell–matrix interac-
tions and signaling through adhesion molecules including integrins
that may modulate ventricular growth in crosstalk with circulating
growth factors and other humoral mediators [4–12].
Recently, a group of small membrane vesicles naturally released
from mammalian cells have been implicated as a new tool for cardiac
cell communication [13–15]. These extracellular vesicles have a ﬂuid
lipid bilayer and contain a speciﬁc set of proteins, genetic materials,
and lipids [13–15]. The types of membrane vesicles produced from car-
diac cells include apoptotic bodies, microvesicles and exosomes [15].
These different vesicles are distinguished from one to another on the
basis of their subcellular origin, size, and content. Apoptotic bodies
(1–5 μm in diameter) are released from the plasma membrane of cells
as blebs when they undergo apoptosis [14–16]. They contain a variety
of cellular organelles, intracellular fragments, histones and even
fragmented DNA and can be detected by extensive amounts of
phosphatidylserine. Apoptotic bodies are considered to be mobile as
they have the ability to ﬂoat on a sucrose substance with a density be-
tween 1.16 and 1.28 g/mL [14–16]. While the exact role of apoptotic
bodies is not fully understood, it is believed that apoptotic bodies
could be used in activating cell signals to promote the elimination of
Fig. 1. The generation of microvesicles and exosomes. Microvesicles (MVs) are formed directly by outward budding or blebbing of the plasma membrane. Speciﬁc loading of membrane
proteins, lipids and RNAs to theMVs is known to occur, but the exactmolecularmechanism are largely unknown. Biogenesis of exosomes is initiatedwith inward budding of the cellmem-
brane, with speciﬁc membrane proteins/receptors incorporated, to form early endosomes. Subsequently, the cargo is packaged into intraluminal vesicles (ILVs) upon second inward bud-
ding of the early endosome membrane, and then transformed into multivesicle bodies (MVBs). Four different mechanisms have been described to facilitate the cargo loading: 1) ESCRT
machinery and associated proteins; 2) lipid rafts; 3) higher-ordered oligomerization; and 4) segregation into microdomains by ceramide. MVBs can then fuse with the lysosomal mem-
brane and release ILVs for degradation. Alternatively, MVBs fuse with the plasma membrane and release ILVs into the extracellular space as exosomes, a process which is regulated by
Rab27a, Rab11, Rab35, WNT5A, SNAREs, glycosphingolipids and ﬂotillins, etc.
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generated from cells by a direct outward budding of the cell membrane
when they are exposed to certain stimuli including exposure to pro-
thrombotic and pro-inﬂammatory as well as cellular differentiation
and senescence [14–16]. Unlike apoptotic bodies, microvesicles ﬂoat
on a different sucrose gradient of 1.04–1.06 g/mL and are usually de-
rived from platelets, endothelial and red blood cells [15]. Microvesicles
contain a variety of bioactive molecules that include a variety of adhe-
sive structures, cytokines, chemokines, cytoplasmic proteins, mem-
brane proteins, cellular receptors, non-coding RNA, and even mRNA
andmiRNAs. The various different proteinmarkers formicrovesicles in-
clude integrins, selectins, and the CD40 ligand [15]. Exosomes are types
of extracellular vesicles whose sizes range between 30–100 nm and
ﬂoat to a density ranging from 1.13–1.19 g/mL using ultracentrifugation
on linear sucrose gradient (2 M–0.25 M sucrose) [15–18]. They have
very unique qualities that greatly set them apart from other extracellu-
lar vesicles (apoptotic bodies andmicrovesicles). Secretion of exosomes
from viable cells was proposed to be a mechanism through which cells
discard their cellular waste [19–22]. However, over the past years,
exosomes have emerged as important players for inter-cellular commu-
nication that are involved both in normal physiology, e.g. cardiac devel-
opment, myocardial angiogenesis, and vesicle formation during
reticulocytematuration [13,15,20–22], and in pathophysiological condi-
tions, e.g. progression of cancer, liver disease, immune-defective dis-
ease, and neurodegenerative disease [16,23–25]. In this review, we
will focus on exosomes and their role in cardiac patho-physiology. Spe-
ciﬁcally, wewill: 1) discuss how to regulate exosomebiogenesis and se-
cretion, 2) summarize the advances on the detrimental and beneﬁcial
role of exosomes in cardiac remodeling, and 3) discuss the therapeutic
potential of exosomes in cardiovascular diseases.
2. Biogenesis and secretion of exosomes
2.1. Exosome biogenesis
The term “exosomes”was coined by Johnstone et al. [21] in their in-
vestigation of vesicle formation during reticulocyte maturation. Since
their initial discovery, much has been learned about the biogenesis of
exosomes. Unlike microvesicles that are derived from the direct out-
ward blebs of plasma, exosomes are generated within the endosomal
network, beginning with the inward budding of the cell membrane to
form early endosomes, followed by second inward budding of the
endosomal membrane to form the various intraluminal vesicles (ILVs)
(late endosomes). The late endosomes containing ILVs are also called
multivesicular bodies (MVBs). Finally, the MVBs may fuse with the
cell membrane, releasing its ILVs in an exocytotic fashion to theextracellular environment. These ILVs are then referred to as exosomes.
Alternatively, the MVBs move towards the perinuclear area of the cell
where they can directly fuse with lysosomes, creating hybrid organelles
where endocytosed cargos are degraded. The process of exosome bio-
genesis is summarized in Fig. 1.
Nowadays, the molecular mechanisms of ILV (exosome) formation
and sorting of endosomal proteins into these vesicles are partially un-
derstood. The best described machinery that drives the process of
MVB formation is coordinated by the endosomal sorting complexes re-
quired for transport (ESCRT) system, which has been widely reviewed
recently in the literature [26–29]. In brief, this machinery consists of
four soluble multi-protein complexes, called ESCRT-0, ESCRT-I, ESCRT-
II and ESCRT-III, and its associated proteins. ESCRT-0 is responsible for
cargo clustering in an ubiquitin-dependent manner; ESCRT-I and
ESCRT-II induce bud formation; ESCRT-III drives vesicle scission, and
the accessory proteins (especially the VPS4 ATPase) allow dissociation
and recycling of the ESCRTmachinery. Recently, Colombo et al. [30] per-
formed an RNA interference screen targeting 23 components of ESCRT
complex and associated proteins in HeLa cells. They observed that de-
pletion of HRS, STAM1 (ESCRT-0 members), and Tsg101 (ESCRT-I com-
ponent) inhibited exosome biogenesis; by contrast, silencing of VPS4b
(ESCRT-III member) promoted exosome formation. Notably, Colombo
et al. [30] observed that members of ESCRT-II did not have any inﬂu-
ences on exosome biogenesis/release in HeLa cells. Of interest, several
recent studies show that the ESCRT-III-associated protein, ALIX, can
augment intraluminal budding of vesicles in endosomes and enhance
CD63-positive exosome biogenesis in primary dendritic cells (DCs)
and muscle cell line C2C12 [31–33].
Although many studies use ESCRT silencing as a tool to inhibit bio-
genesis of exosomes, one should be aware that ESCRT-independent
mechanisms are also involved in the ILV formation and exosome bio-
genesis [34,35]. Thesemechanisms are associated with proteolipid pro-
teins, tetraspanins or heat shock proteins (see reviews elsewhere [26]).
Currently, it remains obscure whether these multiple mechanisms of
biogenesis of exosomes/ILVs can occur in a single MVB, or different
MVB populations can co-exist within the cell. In addition, it is not
completely known how to decide different MVB subpopulations' fate
for either lysosomal degradation or exosomal release. Future studies
will be needed to clarify such issues.
2.2. Exosome secretion
Exosomes can be released from the cell by twomechanisms: consti-
tutive or inducible. The constitutive secretion pathway is regulated by
certain RAB GTPases (Rab27a/b, Rab11 and Rab35), heterotrimetric G-
protein, WNT5A, glycosphingolipids and ﬂotillins [36–41]. On the
3S. Ailawadi et al. / Biochimica et Biophysica Acta 1852 (2015) 1–11other hand, the inducible secretion is regulated by stress stimuli includ-
ing aberrant intracellular calcium release, DNA damage, thrombin, heat
shock, hypoxia and lipopolysaccharide (LPS) stimulation [42–51]. For
example, we and others have shown that a low dose of H2O2 (20 μM)
can stimulate cardiomyocytes to produce exosomes [48–50]. Recent
studies have also shown that ischemic preconditioning can induce
exosome secretion from the heart [52]. In addition, change in mem-
brane pHhas been shown to trigger the secretion of exosomes fromvar-
ious cell types [49,53].
Regardless of whether it is a constitutive or inducible release, the
ﬁnal step of exosome secretion requires the fusion of MVBs with the
plasma membrane. This process possibly involves a speciﬁc combi-
nation of Soluble N-ethylmaleimide-sensitive factor-attachment
protein receptors (SNAREs): vesicular SNAREs (v-SNAREs, localized
on MVBs) interact with target SNAREs (t-SNAREs, localized on the
intracellular side of the plasma membrane), to form a membrane-
bridging SNARE complex, responsible for membrane fusion [54,55].
2.3. Molecular composition of exosomes
Increasing evidence shows that exosome composition contains both
a common and a speciﬁc set of DNA, RNA and proteins (see database
available at www.exocarta.org; www.evpedia.info) [56,57]. The com-
mon set of exosomal proteins that have been identiﬁed are found in
parent's cell membranes of endocytic compartment or the plasma
membrane, also in the cytosol, the Golgi, even the nucleus, but rarely
the endoplasmic reticulum or mitochondria [56–58]. The typical mem-
brane proteins encased in exosomes include GPI-anchored proteins,
Tetraspanins (CD81, CD82 CD63, and CD9) and receptors [i.e., Tumor
Necrosis Factor Receptor 1 (TNFR1)]. Other typical types of molecules
wrapped in exosomes include: 1) luminal proteins such as annexin 2
and cytokines; 2) antigen-presentation (MHC-I, MHC-II) and co-
presentation molecules (CD86), cell adhesion (integrins, MFGE8, etc.),
cell structure and motility (actins, myosin, tubulin, etc.); 3) heat shock
proteins and chaperones (Hsp90, Hsp70, Hsp60, Hsp20, αB-
Crystalline); 4) metabolic enzymes (β-enolase, fatty acid synthase,
glyceraldehyde-3-phosphate dehydrogenase, peroxidases, pyruvate ki-
nase); 5) proteins involved in exosome biogenesis (ESCRT complex, i.e.
Tsg101, Alix); 6) signaling proteins (kinases, 14-3-3, GTPaseHras, RhoA,
RAP1B, guanine nucleotide-binding protein subunits—G proteins, etc.);
7) proteins involved in transcription and protein synthesis (transcrip-
tion factors, histones, ribosomal proteins, ubiquitin, etc.), and8)proteins
involved in trafﬁcking and membrane fusion (Annexins, Rab protein
family, ARF).
In addition to a common set of proteins, it has been characterized
that exosomes display a particular lipid organization and composition
(see reviews elsewhere [18,59,60]). A recent unexpected ﬁnding
showed that exosomes contain double-stranded DNA, mRNA and non-
coding RNA (microRNA and lncRNA) [61–64]. Importantly, we and
others have demonstrated that these exosomal mRNA and microRNA
are functional in recipient cells [65–69]. This suggests that the exchange
of exosome contents between cells may represent an effective and efﬁ-
cient inter-cellular communication. Furthermore, it is now known that
protein and RNA sorting into exosomes is highly regulated by various
patho-physiological stress stimuli and disease conditions [46,64]. This
allows cells to produce tailor-made exosomes with different functional
characteristics, reﬂective of their parent cell status. In this regard, any
stress or disease conditions may be mirrored in the contents of the
exosomes, which can be used to develop future biomarkers for the diag-
nosis and prognosis of diverse cardiovascular disease.
3. Pathological effects of exosomes on cardiac remodeling
At present, exosomes have been implicated to mediate cell-to-cell
communication through different mechanisms of interaction with re-
cipient cells, including: 1) direct ligand–receptor interaction, resultingin activation of downstream signaling, 2) extracellular proteases cleave
exosomalmembrane proteins, releasing soluble ligands that bind to tar-
get receptors of recipient cells, 3) directmembrane fusion, leading to re-
lease of exosomal contents into recipient cells, and 4) internalization of
exosomes by endocytic mechanisms (phagocytosis, macropinocytosis
or receptor-mediated endocytosis) [70]. Considering that the multiple
properties of exosomes (reviewed above) and the secretion of
exosomes from a variety of different cell typeswithin the heart, it is rea-
sonable to expect that exosomes are likely to be involved in many car-
diovascular physiological and pathological disorders. However, the
published studies on such issues are scarce. This may be ascribed to ei-
ther a lack of knowledge or some technical difﬁculties on exosomes. As a
matter of fact, we only collect and summarize a small number of recent
publications that investigated the roles of exosomes in cardiomyocyte
hypertrophy, peripartum cardiomyopathy, diabetes-, and sepsis-
induced cardiomyopathy, as reviewed below.3.1. Exosomes in cardiomyocyte hypertrophy
It is now known that cardiac stress (i.e. systemic hypertension, car-
diac valve disease, andmyocardial infarction) can lead to cardiomyocyte
hypertrophy, ﬁbroblast proliferation, and secretion of extracellular ma-
trix proteins and proinﬂammatory cytokines [71–73]. These ﬁbroblast-
derived mediators may act in either an autocrine or paracrine fashion
between ﬁbroblasts and cardiomyocytes to further stimulate cardiac re-
modeling [73,74]. Notably, cardiomyocytes comprise only 56% (mouse),
30% (rat), and 28% (human) of all the cells in the healthy adult heart;
whereas cardiac ﬁbroblasts have been reported to make up 27%
(mouse), 64% (rat), and 70% (human) of total cardiac cells [75]. Tradi-
tionally, cardiac ﬁbroblasts are considered to play passive roles in the
heart and to be solely responsible formaintaining homeostasis of extra-
cellular matrix proteins, including type I and III collagens and ﬁbronec-
tin [76]. However, when co-cultured with cardiac ﬁbroblasts or treated
with conditioned ﬁbroblast media, adult murine cardiomyocytes devel-
op hypertrophy [77,78]. This suggests that cardiac ﬁbroblast may be ac-
tive participants in cardiomyocyte remodeling, but the underlying
mechanisms of ﬁbroblast-cardiomyocyte communication are not yet
fully understood.
Recently, Bang and co-workers [68] reported a uniquemechanism in
which cardiac ﬁbroblasts promote the hypertrophic response of
cardiomyocytes through exosomal transfer of miR-21* (Fig. 2). They
ﬁrstly identiﬁed that cardiac ﬁbroblast produce and secret exosomes.
Using a RNA sequencing approach, these authors analyzed that 388 rat
miRNAs and 50miRNAswere found to be enriched in exosomes derived
from neonatal rat cardiac ﬁbroblasts. Interestingly, they observed that
25.5% of ﬁbroblast exosomal miRNAs were so called “star” miRNAs,
thepassenger (star) strand that is oftendegradedwithin a cell. In partic-
ular, the levels of miR-21* were signiﬁcantly higher in exosomes,
whereas miR-21 expression was higher in their donor ﬁbroblasts,
when compared to each other. This data indicates thatmiR-21* is selec-
tively packaged into exosomes. Nonetheless, it is too early to conclude
that miRNAs remain inside of donor cells, whereas miRNAs* may be
kicked out of cells through exosomes. The most important ﬁnding by
Bang and colleagues [68] is that, ﬁbroblast-derived exosomal miR-21*
can be takenupby cardiomyocytes, which is dependent on temperature
and actin. Of signiﬁcance, such exosomal miR-21*, once released within
cardiomyocytes, is functional and down-regulates the expression of
SORBS2 (sarcoplasmic protein sorbin and SH3 domain-containing pro-
tein 2) and PDLIM5 (PDZ and LIM domain 5), leading to a substantial in-
crease in cardiomyocyte cell size.Moreover, the study by Bang et al. [68]
may support previous ﬁndings showing that miR-21* was detected in
pericardialﬂuid ofmicewith transverse aortic constriction-induced car-
diac hypertrophy [79], thus conﬁrming in-vivo thatmiR-21* plays a crit-
ical role in regulation of the cardiac ﬁbroblast secretome and in
determining a hypertrophic response.
Fig. 2.Under stress conditions, cardiacﬁbroblasts secretmiR-21*-enriched exosomes,which are taken upby cardiomyocytes, leading to elevation ofmiR-21*. Consequently, the expression
levels of SORBS2 and PDLIM5 are down-regulated in cardiomyocytes, resulting in cardiomyocyte hypertrophy.
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undesirable pathologic hypertrophy of cardiomyocytes through
exosomes and theirmiRNA cargo. However,many questions remain un-
clear. For example, the development of ﬁbroblast during cardiomyopa-
thy involves multiple types of pro-ﬁbrotic cells which may be derived
from epithelial–mesenchymal transition (EMT), endothelial–mesen-
chymal transition (EndMT), perivascular cells, circulating monocytes/
ﬁbrocytes, or bone marrow originated progenitor cells. Therefore, it
will need to clarify whether and how exosomes contribute to such a
process of cardiacﬁbrosis. Given that cardiac ﬁbroblast not only insulate
myocyte bundles but also integrate to myocytes through connexin pro-
teins, it will be an urgent need to address whether cardiac exosomes
play a role in cardiac electrophysiology. In addition, it will need to inves-
tigate whether exosomes are involved in both synthesis and degrada-
tion of extracellular matrix to form ﬁbrosis in the heart.
3.2. Exosomes in peripartum cardiomyopathy
Peripartumcardiomyopathy (PPCM) is a very dangerous pregnancy-
associated cardiomyopathy that resides in a large population of women
[80,81]. It is characterized by sudden heart failure during the lastmonth
of pregnancy and/or in the ﬁrst fewmonths of postpartum. A 16-kDa N-
terminal prolactin fragment (16K PRL), cleaved from the full-length
nursing hormone prolactin (PRL) by cathepsin D, is believed to be aFig. 3. In peripartum cardiomyopathy (PPCM) patients, cathepsinD cleaves nursing hormone pr
both cardiac ﬁbroblasts and endothelial cells to release miR-146a-enriched exosomes, which
cardiomyocytes can down-regulate the expression of Erbb4, Notch1, and Irak1, leading to slo
PRL stimulates endothelial cells to activate NF-κB, which up-regulates miR-146a expressio
angiogenesis.potential factor in initiating PPCM [82]. The underlying molecular
mechanisms, however, remain obscure. Recently, Halkein et al. [69] re-
ported that 16K PRL not only induced the expression of miR-146a in en-
dothelial cells (ECs), leading to inhibition of angiogenesis, but also
enhanced the release ofmiR-146a-enriched exosomes from ECs (Fig. 3).
These endothelial exosomes can be taken up by cardiomyocytes,
resulting in the elevation of miR-146a levels. Consequently, the expres-
sion of Erbb4, Notch1, and Irak1 (targets of miR-146a)was decreased in
cardiomyocytes, leading to impaired metabolic activity and contractile
function. These ﬁndings provide evidence that shows a miRNA-based
intercellular communication system between ECs and cardiomyocytes
via exosomes. Moreover, in situ hybridization in postpartum STAT3-
knockout mouse hearts mainly detected miR-146a in ECs and other
nonmyocyte cardiac cells, such as cardiac ﬁbroblasts. This suggests
that in addition to ECs, ﬁbroblasts may also be a source of exosomal
miR-146a in hearts exposed to 16K PRL.
Of interest, Halkein et al. [69] further observed that levels of
exosomal miR-146a were signiﬁcantly higher in plasma from patients
with acute PPCM (n = 38) than healthy postpartum controls (n =
18) and patients with dilated cardiomyopathy (n= 30). It is important
to note here that 12 PPCM patients who recovered after being treated
with standard therapy for heart failure (beta blocker and ACE inhibitor)
and 2.5–5.0 mg/d bromocriptine for 6–8 weeks, had the levels of circu-
lating exosomal miR-146a restored to normal range. Thus, exosomalolactin (PRL) to generate an antiangiogenic 16-kDa fragment, 16K PRL. 16K PRL stimulates
transport miR-146a to cardiomyocytes. The exosome-mediated elevation of miR-146a in
wed metabolism and impaired contractile function in cardiomyocytes. In addition, 16K
n, leading to decreased levels of NRAS, IRAK1 and TRAF6 and consequently, inhibiting
Fig. 4. In type-2 diabetic rat hearts, miR-320 is up-regulated, whereas Hsp20 is down-regulated in cardiomyocytes. Accordingly, exosomes released from diabetic cardiomyocytes contain
higher levels ofmiR-320, comparedwith those fromhealthy cardiomyocytes. The exosomalmiR-320 is then transported to endothelial cells, resulting indecreased levels of IGF-1, Ets2 and
Hsp20 and thereby, inhibiting angiogenesis in diabetic hearts. By contrast, healthy cardiomyocytes can secretmiR-126- andHsp20-enriched exosomes,which transfermiR-126 andHsp20
to endothelial cells, leading to angiogenesis.
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agnosis and risk stratiﬁcation of patients with peripartum heart failure.
3.3. Exosomes in diabetic cardiomyopathy
Diabetes affects approximately 8% of the United States population
and it is predicted that, over 400 million people by 2030 will have
cases of diabetes [83]. Diabetes mellitus is a group of metabolic diseases
characterized by high blood glucose either due to lack of (type 1) or re-
sistance to (type 2) insulin [84]. Early in the course of diabetes, high glu-
cose levels in the bloodstream can lead to endothelial dysfunction and
microvascular rarefaction [85,86]. Interestingly, insufﬁcient myocardial
angiogenesis is the major manifestation of diabetes-caused ischemic
cardiovascular disease [87]. Within themammalian heart, it is well rec-
ognized that endothelial cells play a critical role in cardiomyocyte sur-
vival and myocardial contraction [88]. However, in response to stress
conditions (i.e. hyperglycemia), whether cardiomyocytes have an
ability to affect endothelial cell function remains largely unknown. Re-
cently, we and others have observed that exosomes derived from
cardiomyocytes harbor a variety of mRNAs, miRNAs and proteins,
which may be transferred to the adjacent endothelial cells and modu-
late their function [48,49,67,89]. In particular, we showed that when
cardiac endothelial cells (ECs) were co-cultured with cardiomyocytes
derived from type 2 diabetic Goto-Kakizaki (GK) rats, EC proliferation
and migration were signiﬁcantly inhibited, compared with EC culture
alone [67]. By contrast, co-culture of ECs with cardiomyocytes isolated
from healthy rats promoted EC proliferation and migration [67]. Thus,
these data provide evidence that normal conditions of cardiomyocytes
may beneﬁt ECs, whereas diabetic myocytes may impair EC function
(Fig. 4). Of interest, either beneﬁcial or detrimental effects of
cardiomyocytes on ECswere eliminatedwhen treatedwith exosome in-
hibitor GW4869. Our further investigations revealed that exosomesderived from diabetic GK cardiomyocytes contain higher levels of
miR-320, and lower levels of miR-126 and Hsp20 proteins, compared
with exosomes collected from healthy cardiomyocytes [67]. Important-
ly, the cardiomyocyte exosomalmiR-320 can be transferred to endothe-
lial cells and consequently, down-regulates the expression of IGF-1,
Hsp20, and Ets-2, leading to inhibition of EC proliferation, migration
and tube formation [67]. Therefore, our study may provide a novel
mechanism underlying the impairment of myocardial angiogenesis in
diabetes which may be caused by secretion of anti-angiogenic
exosomes from cardiomyocytes (Fig. 4).
3.4. Exosomes in septic cardiomyopathy
Cardiovascular dysfunction is a major player contributing to mortal-
ity associated with sepsis, a disease initiated by local severe infection
[90]. There is compelling evidence thatmyocardial depression is present
in N40% of sepsis patients [91], and that exosomesmay be involved [92].
Sepsis is triggered by a reactive immune response to an infection that
can potentially result in mass deterioration of multiple organs [90]. In-
ﬂammation induced by sepsis results in blood clotting that restricts
blood ﬂow, thus causing a lack of supply of nutrients and oxygen to
vital organs, like the heart. As a matter of fact, cardiovascular dysfunc-
tion is a major factor contributing to mortality associated with sepsis
[91]. Numerous studies have shown that biventricular dilation and
decrease in ejection fraction are associated with septic patients [91].
Much of prior work has implicated cytokines (IL-6 and TNFα) and
reactive oxygen/nitrogen species (nitric oxide, superoxide, and
peroxynitrite) as myocardial depressors [90]. However, several recent
studies indicate that the presence of exosomes in the plasma of sepsis
patients may cause vascular and cardiac dysfunctions as well as coagu-
lation in sepsis [51,92,93]. In particular, Gambim et al. [51] reported that
in sepsis, both increased generation of nitric oxide (NO) and the
Fig. 5. Sepsis can cause higher levels of lipopolysaccharide (LPS) and nitric oxide (NO) in the blood, which stimulate platelets to secret inﬂammatory exosomes. Such exosomes are
enriched with NADPH, NOS, PGI, ICAM-1 and less miR-223, which activate ROS/RNS signaling pathways, increase NO production and activate caspase-3 in both endothelial cells and
cardiomyocytes, resulting in cell apoptosis and dysfunction and consequently, cardiomyopathy.
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septic exosomes contain higher levels of NADPH oxidase, nitric oxide
synthases (NOS) and protein disulﬁde isomerase (PDI) than healthy
exosomes, as evidenced by Western-blotting. Importantly, these au-
thors observed that NO-induced and human septic platelet-derived
exosomes induced caspase-3 activation and apoptosis of target endo-
thelial cells through generation of active ROS/RNS by NADPH oxidase
and NO synthase type II (Fig. 5). Azevedo et al. [92] further provided ev-
idence that circulating platelet-derived exosomes from septic patients
induced a decrease in myocardial contractility in isolated rabbit heart
and rat papillary muscle preparations. These detrimental effects of
exosomes were enhanced by pre-exposure to LPS. They conﬁrmed
that septic platelet-derived exosomes contain NOS, which can generate
NO in exosomes and induce NO production in the heart. More recently,
numerous studies have proﬁled circulating exosomal miRNAs in septic
patients [63]. Speciﬁcally, the levels of exosomal miR-223 are signiﬁ-
cantly lower in the blood of non-survival septic patients, compared
with survivors [94]. Of interest, reduced miR-223 may increase the ex-
pression of miR-223 targets (e.g. ICAM-1, IL-6, and IL-1β) [95–97]. Con-
sequently, these increased target proteins may be enriched in septic
exosomes and contribute to myocardial depression (Fig. 5). Put togeth-
er, sepsis-induced cardiomyopathy may be mostly ascribed to both an
increased number of exosomes and an intrinsic property of exosome
(e.g. enriched NOS, reduced miR-223).
4. Protective effects of exosomes in the myocardium
As reviewed above, exosomes derived from disease conditions elicit
detrimental effects on cardiac remodeling. Recent studies have also
demonstrated that exosomes collected from ischemic preconditioning
or various stem cells provide cardioprotection, which may have thera-
peutic potential in the treatment of cardiovascular diseases. In the fol-
lowing sections, we will summarize recent ﬁndings on the role of
stem cell-derived, stress-preconditioned and gene-modiﬁed cell-
derived exosomes in cardiac protection including enhanced myocardial
angiogenesis, reduced oxidative stress, limited inﬂammatory response,
decreased cardiomyocyte death and myocardial infarction size (Fig. 6).
4.1. Mesenchymal stem cell-derived exosomes confer protection in cardio-
vascular diseases
Various kinds of stem cells (embryonic stem cells, adult stem cells,
and induced pluripotent stem cells) have been extensively investigated
for the therapeutic potential in cardiovascular disease [98–100]. It was
previously thought that stem cell therapy acts to regenerate tissue
through replication and then differentiation, but recent studies indicate
that the beneﬁcial effects of adult stem cells in the repair of cardiac
tissue is through the release of paracrine and autocrine factors [101]. In-
deed, stem cells can secret numerous types of factors/molecules, includ-
ing proteins, microRNAs, growth factors, antioxidants, proteasomes,
microvesicles and exosomes. In particular, exosomes has garnered aspeciﬁc attention in cell-free-based stem cell therapy for cardiovascular
disease.
Lai et al. [102] ﬁrst showed that human ESC-derived mesenchymal
stem cells (MSCs) secreted 50- to 100-nm membrane vesicles. Using
an ex-vivo Langendorff model of ischemia/reperfusion injury, they ob-
served that these puriﬁed exosomes were able to reduce infarct size in
mouse hearts. Arslan et al. [103] further demonstrated that a single in-
travenous bolus of exosomes 5 min prior to reperfusion reduced infarct
size by 45% inmice. Importantly, they found that exosome treatment re-
stored energy depletion and redox state in mouse hearts within 30min
after I/R, evidenced by elevation of ATP and NADH levels, and reduction
of oxidative stress. This can be interpreted that MSC-derived exosomes
contain all ﬁve enzymes [namely glyceraldehyde 3-phosphate dehydro-
genase (GAPDH), phosphoglycerate kinase (PGK), phosphoglucomu-
tase (PGM), enolase (ENO) and pyruvate kinase m2 isoform (PKm2),
see database available at www.exocarta.org] required for ATP genera-
tion. In addition, active CD73 (themajor enzyme responsible for the for-
mation of extracellular adenosine from released adenine nucleotides)
and the phosphorylated PFKFB3 (which upregulates phosphofructose
kinase) are also wrapped in MSC-derived exosomes [103]. Moreover,
exosome treatment could reduce systemic inﬂammation in mice after
myocardial I/R [103]. Therefore,MSC-derived exosomesmay have pow-
erful therapeutic potential for patients suffering from acute myocardial
infarction.
Similarly, Lee et al. [104] reported that the anti-inﬂammatory activ-
ity in mouse bone marrow-derived mesenchymal stem cells (MSCs) is
associated with exosomes. Using a murine model of hypoxia-induced
pulmonary hypertension (HPH), these authors demonstrated that
MCS-derived exosome (MEX)delivery in-vivo suppressedHPH and vas-
cular remodeling. Moreover, hyper-proliferative signals were also
blocked by MEX treatment, as evidenced by the suppression of signal
transducer and activator of transcription-3 (STAT3) phosphorylation,
resulting in increased lung levels of miR-204, a microRNA enriched in
distal pulmonary arterioles that is downregulated in both human PH
and experimental models of disease. The data provided by Lee et al.
[104] point to exosomes as the key effectors of MSC paracrine function.
However, their work did not identify the critical components encased in
these exosomes.
4.2. Hematopoietic stem cell-derived exosomes promotes myocardial
angiogenesis
It is previously hypothesized that hematopoietic stem cells (HSCs)
could repair cardiac tissue by differentiating into cardiomyocytes
[105]. However, numerous studies have shown that few of the
transplanted HSC survive and even fewer of the cells become
cardiomyocytes [106]. Nonetheless, it has been observed that the trans-
plantation of these HSCs improved cardiac function in both animal
models and human patients [107–110]. This may be the result of a vari-
ety of paracrine factors including vascular endothelial growth factor
(VEGF), FGF, HGF, and IGF, released from implanted HSCs. Recently, a
study by Sahoo et al. [111] showed that human CD34+ stem cells had
Fig. 6.Multiple sources of stem cells, stress-preconditioned cells and gene-modiﬁed cells can yield cardio-protective exosomes. These protective exosomes, when injected into hearts, can
interact with endothelial cells, cardiomyocytes, ﬁbroblasts and other types of cells within hearts by endocytosis, receptor/ligand-mediated action, or membrane fusion, resulting in en-
hanced angiogenesis, reduced oxidative stress, decreased cell apoptosis/necrosis, and limited inﬂammatory response.
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phosphatidylserine and TSG101. By the in vitro method, it was found
that CD34+-exosomes replicated the angiogenic activity of the CD34+
cells by enhancing endothelial cell viability, proliferation and tube-like
formation on Matrigel. In the in vivo studies, these authors observed
that both CD34+-cells and CD34+-exosomes induced the formation of
vessel-like endothelial structures, accompanied by a signiﬁcantly in-
creased proportion of endothelial cells in the Matrigel plug. In the cor-
neal angiogenesis assay, pellets containing CD34+-exosomes, but not
CD34−-exosomes, were associated with signiﬁcantly greater vessel
growth. Hence, these ﬁndings indicate that the CD34+-exosomes are
the key paracrine component of CD34+-cell-induced vessel growth.
Nonetheless, the mechanisms underlying CD34+-exosome-mediated
angiogenesis are not clearly understood. It could be ascribed to
exosomal receptor-induced activation of angiogenic signaling cascades
or the overall transfer of exosomal contents (proteins/RNAs) into the
cytosol of endothelial cells. Indeed, Sahoo et al. [111] has presented
data demonstrating that CD34+-exosomes are highly enriched with
pro-angiogenic miR-126 and miR-130a, compared with CD34−-
exosomes. However, the extent to which these exosomal miRs are
transferred and induce any molecular changes in the recipient cells re-
mains to be clariﬁed.
While the beneﬁt of CD34+-cell therapy on functional recovery after
ischemic injury could be induced primarily through the exosome-
mediated transfer of angiogenic factors to surrounding cells, both viabil-
ity and angiogenic quality of autologous CD34+-cells decline with ad-
vanced age [112,113]. In this regard, Mackie et al. [114] recently
attempted to genetically modify CD34+-cells with the sonic hedgehog
(Shh) gene (CD34Shh) for enhancing their angiogenic quality. They ob-
served that treatment with CD34Shh induced robust increases in capil-
lary development within the infarct border zone, accompanied by
reduced infarct sizes. Importantly, they found that CD34Shh deposits a
greater amount of Shh in exosomes as compared with other Shh-
modiﬁed cell types. Shh-containing exosomes derived from CD34Shh
are capable of transferring Shh to other cell types (endothelial cells
and ﬁbroblasts) and thereby, activating the Shh signaling pathway.
Thus, exosome-mediated delivery of Shh to ischemic myocardiummay represent a major mechanism explaining the observed preserva-
tion of cardiac function in mice treated with CD34Shh cells.
4.3. Cardiac progenitor cells-derived exosomes provide cardioprotection
Cardiac progenitor cells (CPCs) can also release exosomes into
their environment and those exosomes contain matrix metallopro-
teinases (MMPs) and extracellular matrix metalloproteinase inducer
(EMMPRIN) that all aid in the breakdown of the extracellular matrix
as well as activate MMP [115]. In addition, GTAT4-responsive miR-
451 is highly enriched in these exosomes [116,117]. As a matter of
fact, Vrijsen et al. [115] observed that CPC-derived exosomes can
stimulate the migration of endothelial cells in an in vitro scratch
assay. Chen et al. [116] found that in vivo delivery of CPC-exosomes
in an acute mouse myocardial ischemia/reperfusion model inhibited
cardiomyocyte apoptosis by about 53% in comparison with PBS con-
trol. Together, these studies implicate exosomes as the important
cardioprotective component in CPC-mediated paracrine effects.
Currently, it is recognized that cardiac progenitor cells can be
clonally expanded from murine and human myocardial biopsy spec-
imens and form “spheres” in vitro which is referred to as
cardiospheres (CSs) [118–121]. Because CSs contain both primitive
cells and committed progenitors for the three major cell types pres-
ent in the heart (cardiomyocytes, endothelial cells, and smoothmus-
cle cells), they represent an attractive cell source for cardiac
regeneration. Indeed, numerous studies have demonstrated that
cardiosphere-derived cells (CDCs) can stimulate regeneration, an-
giogenesis, and functional improvement in the infarcted human
heart [122–124]. Most recently, Ibrahim et al. [125] showed that
CDC-derived exosomes can replicate CDC-induced therapeutic ef-
fects, and blockade of exosome production negates the beneﬁcial ef-
fects of CDCs on the infarcted mouse hearts. They further identiﬁed
miR-146a as being particularly enriched in CDC exosomes. Of inter-
est, miR-146a may largely contribute to the protective effects of
CDC-exosomes, but does not sufﬁce to confer comprehensive thera-
peutic beneﬁt alone. Hence, other miRNAs (i.e. miR-22, miR-24) in
the repertoire may exert synonymous or perhaps synergistic effects
Table 1
Pathologic effects of exosomes in the heart.
Exosome sources Key ﬁndings (function of exosomes) Cargo responsible for effect Refs
Neonatal rat cardiac ﬁbroblasts Promote cardiomyocyte hypertrophy miR-21* [68,133]
Goto-Kakizaki (GK) rat cardiomyocytes Inhibit myocardial endothelial cell promotion, migration and tube formation miR-320 [67]
Platelets from patients with sepsis Induce endothelial cell apoptosis and cardiac dysfunction NADPH, NOS, PDI [92,93]
16K PRL-treated HUVECs Reduce metabolic activity in cardiomyocytes miR-146a [69]
Heart and plasma from patients with acute
peripartum cardiomyopathy
miR-146a-enriched exosomes are associated with dilated with cardiomyopathy miR-146a [69]
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dicate that CDC-exosomes contain rich signaling information, and
speciﬁcally the miRNAs transferred by these exosomes, that is capa-
ble of producing regeneration in a murine model of myocardial in-
farction (MI), and confer the same beneﬁts as CDCs without
transplantation of living cells.
4.4. Ischemic-preconditioned (IPC) exosomes mediate cardioprotection
It is well appreciated that ischemic preconditioning (IPC) elicits
strong protective effects against cardiac ischemia/reperfusion (I/R)-in-
duced injury [126,127]. However, the underlying mechanism is still
not completely understood. Recently, Giricz et al. [52] showed that cor-
onary efﬂuent collected from IPC rat hearts contained more extracellu-
lar vesicles (EVs, microvesicles and exosomes) than efﬂuent from
control hearts, as evidenced byWestern blotting. Furthermore, they ob-
served that infarct sizewas signiﬁcantly smaller in hearts perfusedwith
coronary efﬂuent collected from IPC hearts than those hearts perfused
with coronary efﬂuent from control hearts. Of interest, infarct size in
hearts perfused with EV-depleted IPC coronary efﬂuent was similar to
controls. Therefore, the study by Giricz et al. [52] indicates that
microvesicles/exosomes released from IPC hearts are responsible for
the transmission of protective signals in the heart. It is important to
note here, a recent study by Li et al. [128] showed that cardio-
protection elicited by remote ischemic preconditioning (rIPC) was
associated with the elevation of circulating miR-144, which was not in-
cluded in plasmamicroparticles/microvesicles (50–400 nm), but incor-
porated with Argonaute 2. Nonetheless, they observed that the hairpin
precursor miR-144 had a 4-fold increase in the exosome pellet derived
from rIPC plasma [128]. Similarly, Jeanneteau et al. [129] recently ob-
served that microvesicles derived from the blood of animals that
underwent hind limb ischemia/reperfusion failed to decrease myocar-
dial infarct size in rats. Put together, these studies suggest thatTable 2
Protective effects of exosomes in the heart.
Exosome sources Key ﬁndings (function of exosom
Human CD34+ cells; Shh-modiﬁed
CD34+ cells
Promote angiogenesis and reduc
acute myocardial infarction
Human ES9.E1-derived MSCs In myocardial ischemic–reperfu
animals exhibited signiﬁcant pre
geometry and contractile perfor
follow-up.
Human cardiac progenitor cells (CPCs) Inhibit cardiomyocyte apoptosis
after injection of exosomes into
Human fetal heart-derived
progenitor cells
Enhance the migration of human
cells (HMECs), using in vitro scr
Human cardiosphere-derived
cells (CDCs)
Injection of exosomes into injur
the regenerative and functional
transplantation.
Mouse mesenchymal stem cells
subjected to two cycles of anoxia (30 min)
and re-oxygenation (10 min) (IPC).
In vivo delivery of IPC exosomes
reduces infarction sizes in mous
model.
Mouse mesenchymal stromal cells In the murine model of hypoxic
intravenous delivery of exosome
remodeling and hypoxic pulmon
Rat hearts upon three cycles of global ischemia (5 min)
and reperfusion (5 min, IPC) in Langendorff mode.
Exosomes collected from perfus
infarction size in non-preconditexosomes rather than microvesicles (microparticles) contribute to the
propagation of cardioprotective signals. Further studies will deﬁnitely
be needed to elucidate the mechanisms underlying the IPC-exosome-
mediated cardioprotection, using a clinically relevant in vivo model.
Recently, Feng et al. [130] performed a microRNA array for proﬁl-
ing the miRNAs in exosomes released from ischemic-preconditioned
mesenchymal stem cells (MSCs). These MSCs were isolated from
mouse bone marrow and subjected to two cycles of anoxia
(30 min)–reoxygenation (10 min) as ischemic preconditioning
(IPC). Feng et al. [130] observed that the levels of miR-22 were 4.5-
fold higher, accompanied by miR-21 (3.3-fold), miR-210 (3.1-fold),
miR-199a-3p (2.8-fold), and miR-24 (2.5-fold) in exosomes collect-
ed from IPC-MSCs (ExoIPC) than control exosomes (Exonon-IPC). Im-
portantly, in vivo treatment of mice with ExoIPC by direct injection
into infarcted hearts resulted in a signiﬁcant reduction of cardiac
ﬁbrosis and apoptosis, compared with Exonon-IPC-treated hearts. Fur-
thermore, these authors identiﬁed that the ExoIPC-mediated protec-
tive effects are largely associated with transfer of exosomal miR-22
to surrounding cells. However, whether these preconditioned
exosomes contain other beneﬁcial proteins or ligands/receptors re-
mains unclear.
5. Conclusions and future studies
Over the past decade, exosomes have been extensively studied as
miRNA-carriers, as biomarkers for diagnosis of disease, and as a critical
tool for cell-to-cell communication. However, their physiological and
pathological roles in cardiovascular diseases are still vague. As reviewed
above, exosomes derived from different conditions may contain differ-
ent functional factors, which decide their properties; either harmful or
beneﬁcial (Tables 1 & 2). Most studies consistently implicate that dis-
ease messages may be spread around the body through exosomes
(pathological role). But, we do not know whether speciﬁc blockade ofes) Cargo responsible for effect Refs
e infarct size in mice after miR-126, miR-130a, Shh protein [111,114]
sed mice, exosome-treated
servation of left ventricular
mance during 28 days
GAPDH, PGK, PGM, ENO, PKm2,
phosphorylated PFKFB3
[102,103]
and improve cardiac function
rat infarcted hearts.
miR-210, miR-132, miR-146a-3p [134]
microvascular endothelial
atch wound assay.
MMPs and EMMPRIN [115]
ed mouse hearts recapitulates
effects produced by CDC
miR-146a, miR-22, miR-24, miR-210 [125]
ameliorates ﬁbrosis and
e myocardial infarction
miR-21, miR-22, miR-24, miR-199a-3p,
miR-210
[130]
pulmonary hypertension,
s inhibits vascular
ary hypertension.
miR-17 superfamily, miR-204 [104]
ates of IPC hearts attenuate
ioned recipient hearts.
N/A (not available) [52]
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Additionally, while it is well appreciated that stem cell-derived
exosomes have therapeutic potential in cardiovascular disease, the
in vivo mechanisms underlying the exosome-elicited action are not
clear yet. Of interest, Yuan et al. [131] recently observed that only cer-
tainmiRNAswrapped in exosomes/microvesicleswere efﬁciently trans-
ferred to recipient cells, which raises the possibilities that the transfer of
miRNAs is selective and may be regulated by proteins located at either
exosomes or recipient cells. Future studieswill be needed to test this hy-
pothesis. Moreover, the ability of exosomes to transfer lipid, RNA, and
proteins raises very exciting possibilities for future therapeutic uses.
For example, based on the regulatory effects of miR on therapeutic pro-
teins [132,133], we could engineer host cells to overexpress a speciﬁc
miR that is capable to be delivered via exosomes. These engineered
cells can be either encapsulated to provide sustained local delivery or
utilized as “factory” to produce therapeutic exosomes. The latter may
be used as viral-free or cell-free agents in replacement of viral vectors
or intact cells, which offers a safer approach for clinical application. It
is also possible that the pathologic exosomes can be re-uploaded and
be able to replace the harmful factors with beneﬁcial ones. Overall, fur-
ther understanding of pathways involved in exosome biogenesis,
exosomal cargo loading, exosome secretion and exosome uptake will
be of fundamental importance to address how to alter the quality and
quantity of exosomes, as well as therapeutic efﬁcacy for the treatment
of cardiovascular disease.
Conﬂict of interest
The authors conﬁrm that this article content has no conﬂict of
interest.
Acknowledgements
The research in Dr. Guo-Chang Fan's lab is supported by NIH grant
2R01-087861.
References
[1] A.S. Go, et al., Executive summary: heart disease and stroke statistics—2014 up-
date: a report from the American Heart Association, Circulation 129 (2014)
399–410.
[2] M. Ieda, Heart development and regeneration via cellular interaction and
reprogramming, Keio J. Med. 62 (2013) 99–106.
[3] C.A. Souders, S.L. Bowers, T.A. Baudino, Cardiac ﬁbroblast: the renaissance cell, Circ.
Res. 105 (2009) 1164–1176.
[4] D. Tirziu, F.J. Giordano, M. Simons, Cell communications in the heart, Circulation
122 (2010) 928–937.
[5] F. Sheikh, R.S. Ross, J. Chen, Cell–cell connection to cardiac disease, Trends
Cardiovasc. Med. 19 (2009) 182–190.
[6] R. Kakkar, R.T. Lee, Intramyocardial ﬁbroblast myocyte communication, Circ. Res.
106 (2010) 47–57.
[7] V. Lionetti, G. Bianchi, F.A. Recchia, C. Ventura, Control of autocrine and paracrine
myocardial signals: an emerging therapeutic strategy in heart failure, Heart Fail.
Rev. 15 (2010) 531–542.
[8] P. Zhang, J. Su, U. Mende, Cross talk between cardiac myocytes and ﬁbroblasts:
from multiscale investigative approaches to mechanisms and functional conse-
quences, Am. J. Physiol. Heart Circ. Physiol. 303 (2012) H1385–H1396.
[9] S. Cherian, G.D. Lopaschuk, E. Carvalho, Cellular cross-talk between epicardial adi-
pose tissue and myocardium in relation to the pathogenesis of cardiovascular dis-
ease, Am. J. Physiol. Endocrinol. Metab. 303 (2012) E937–E949.
[10] Y. Tian, E.E. Morrisey, Importance of myocyte–nonmyocyte interactions in cardiac
development and disease, Circ. Res. 110 (2012) 1023–1034.
[11] S. Doroudgar, C.C. Glembotski, The cardiokine story unfolds: ischemic stress-
induced protein secretion in the heart, Trends Mol. Med. 17 (2011) 207–214.
[12] L. Pentassuglia, D.B. Sawyer, ErbB/integrin signaling interactions in regulation of
myocardial cell–cell and cell–matrix interactions, Biochim. Biophys. Acta 2013
(1833) 909–916.
[13] M.F. Ribeiro, H. Zhu, R.W. Millard, G.C. Fan, Exosomes function in pro- and anti-
angiogenesis, Curr. Angiogenesis 2 (2013) 54–59.
[14] H. Zhu, G.C. Fan, Extracellular/circulating microRNAs and their potential role in car-
diovascular disease, Am. J. Cardiovasc. Dis. 1 (2011) 138–149.
[15] J.P. Sluijter, V. Verhage, J.C. Deddens, F. van den Akker, P.A. Doevendans,
Microvesicles and exosomes for intracardiac communication, Cardiovasc. Res.
102 (2014) 302–311.[16] E.I. Buzas, B. György, G. Nagy, A. Falus, S. Gay, Emerging role of extracellular vesi-
cles in inﬂammatory diseases, Nat. Rev. Rheumatol. 10 (2014) 356–364.
[17] K.B. Johnsen, J.M. Gudbergsson, M.N. Skov, L. Pilgaard, T. Moos, M. Duroux, A com-
prehensive overview of exosomes as drug delivery vehicles — endogenous
nanocarriers for targeted cancer therapy, Biochim. Biophys. Acta 2014 (1846)
75–87.
[18] A.V. Vlassov, S. Magdaleno, R. Setterquist, R. Conrad, Exosomes: current knowledge
of their composition, biological functions, and diagnostic and therapeutic poten-
tials, Biochim. Biophys. Acta 2012 (1820) 940–948.
[19] E.G. Trams, C.J. Lauter, N. Salem Jr., U. Heine, Exfoliation of membrane ecto-
enzymes in the form of micro-vesicles, Biochim. Biophys. Acta 7 (1981) 63–70.
[20] B.T. Pan, K. Teng, C. Wu, M. Adam, R.M. Johnstone, Electron microscopic evidence
for externalization of the transferrin receptor in vesicular form in sheep reticulo-
cytes, J. Cell Biol. 7 (1985) 942–948.
[21] R.M. Johnstone, M. Adam, J.R. Hammond, L. Orr, C. Turbide, Vesicle formation dur-
ing reticulocyte maturation. Association of plasma membrane activities with re-
leased vesicles (exosomes), J. Biol. Chem. 7 (1987) 9412–9420.
[22] R.M. Johnstone, A. Bianchini, K. Teng, Reticulocyte maturation and exosome re-
lease: transferrin receptor containing exosomes shows multiple plasma mem-
brane functions, Blood 7 (1989) 1844–1851.
[23] M. Record, K. Carayon, M. Poirot, S. Silvente-Poirot, Exosomes as new vesicular
lipid transporters involved in cell–cell communication and various pathophysiol-
ogies, Biochim. Biophys. Acta 2014 (1841) 108–120.
[24] P. Kharaziha, S. Ceder, Q. Li, T. Panaretakis, Tumor cell-derived exosomes: a mes-
sage in a bottle, Biochim. Biophys. Acta 2012 (1826) 103–111.
[25] A. Kalani, A. Tyagi, N. Tyagi, Exosomes: mediators of neurodegeneration, neuropro-
tection and therapeutics, Mol. Neurobiol. 49 (2014) 590–600.
[26] J. Kowal, M. Tkach, C. Théry, Biogenesis and secretion of exosomes, Curr. Opin. Cell
Biol. 29C (2014) 116–125.
[27] J.C. Akers, D. Gonda, R. Kim, B.S. Carter, C.C. Chen, Biogenesis of extracellular vesi-
cles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies, J.
Neurooncol. 113 (2013) 1–11.
[28] J.M. Yang, S.J. Gould, The cis-acting signals that target proteins to exosomes and
microvesicles, Biochem. Soc. Trans. 41 (2013) 277–282.
[29] S. Pant, H. Hilton, M.E. Burczynski, The multifaceted exosome: biogenesis, role in
normal and aberrant cellular function, and frontiers for pharmacological and bio-
marker opportunities, Biochem. Pharmacol. 83 (2012) 1484–1494.
[30] M. Colombo, C. Moita, G. van Niel, J. Kowal, J. Vigneron, P. Benaroch, N. Manel, L.F.
Moita, C. Théry, G. Raposo, Analysis of ESCRT functions in exosome biogenesis,
composition and secretion highlights the heterogeneity of extracellular vesicles,
J. Cell Sci. 126 (2013) 5553–5565.
[31] C.Y. Soo, Y. Song, Y. Zheng, E.C. Campbell, A.C. Riches, F. Gunn-Moore, S.J. Powis,
Nanoparticle tracking analysis monitors microvesicle and exosome secretion
from immune cells, Immunology 136 (2012) 192–197.
[32] M. Guescini, et al., C2C12 myoblasts release micro-vesicles containing mtDNA and
proteins involved in signal transduction, Exp. Cell Res. 316 (2010) 1977–1984.
[33] D.P. Romancino, G. Paterniti, Y. Campos, A. De Luca, V. Di Felice, A. d'Azzo, A.
Bongiovanni, Identiﬁcation and characterization of the nano-sized vesicles re-
leased by muscle cells, FEBS Lett. 587 (2013) 1379–1384.
[34] K. Trajkovic, C. Hsu, S. Chiantia, L. Rajendran, D. Wenzel, F. Wieland, P. Schwille, B.
Brügger, M. Simons, Ceramide triggers budding of exosome vesicles into
multivesicular endosomes, Science 319 (2008) 1244–1247.
[35] T. Kajimoto, T. Okada, S. Miya, L. Zhang, S. Nakamura, Ongoing activation of sphin-
gosine 1-phosphate receptors mediates maturation of exosomal multivesicular
endosomes, Nat. Commun. 4 (2013) 2712.
[36] M. Ostrowski, et al., Rab27a and Rab27b control different steps of the exosome se-
cretion pathway, Nat. Cell Biol. 12 (2010) 19–30.
[37] A. Savina, M. Vidal, M.I. Colombo, The exosome pathway in K562 cells is regulated
by Rab11, J. Cell Sci. 115 (2002) 2505–2515.
[38] C. Hsu, et al., Regulation of exosome secretion by Rab35 and its GTPase-activating
proteins TBC1D10A–C, J. Cell Biol. 189 (2010) 223–232.
[39] M.J. Vidal, P.D. Stahl, The small GTP-binding proteins Rab4 and ARF are associated
with released exosomes during reticulocyte maturation, Eur. J. Cell Biol. 60 (1993)
261–267.
[40] E.J. Ekström, C. Bergenfelz, V. von Bülow, F. Seriﬂer, E. Carlemalm, G. Jönsson, T.
Andersson, K. Leandersson, WNT5A induces release of exosomes containing pro-
angiogenic and immunosuppressive factors from malignant melanoma cells, Mol.
Cancer 13 (2014) 88.
[41] S. Phuyal, N.P. Hessvik, T. Skotland, K. Sandvig, A. Llorente, Regulation of exosome
release by glycosphingolipids and ﬂotillins, FEBS J. 281 (2014) 2214–2227.
[42] A. Savina, M. Furlán, M. Vidal, M.I. Colombo, Exosome release is regulated by a
calcium-dependent mechanism in K562 cells, J. Biol. Chem. 278 (2003)
20083–20090.
[43] A. Lespagnol, D. Duﬂaut, C. Beekman, L. Blanc, G. Fiucci, J.C. Marine, M. Vidal, R.
Amson, A. Telerman, Exosome secretion, including the DNA damage-induced
p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-
null mice, Cell Death Differ. 15 (2008) 1723–1733.
[44] H.F. Heijnen, A.E. Schiel, R. Fijnheer, H.J. Geuze, J.J. Sixma, Activated platelets re-
lease two types of membrane vesicles: microvesicles by surface shedding and
exosomes derived from exocytosis of multivesicular bodies and alpha-granules,
Blood 94 (1999) 3791–3799.
[45] T. Chen, J. Guo, M. Yang, X. Zhu, X. Cao, Chemokine-containing exosomes are re-
leased from heat-stressed tumor cells via lipid raft-dependent pathway and act
as efﬁcient tumor vaccine, J. Immunol. 186 (2011) 2219–2228.
[46] O.G. de Jong, M.C. Verhaar, Y. Chen, P. Vader, H. Gremmels, G. Posthuma, R.M.
Schiffelers, M. Gucek, B.W. van Balkom, Cellular stress conditions are reﬂected in
10 S. Ailawadi et al. / Biochimica et Biophysica Acta 1852 (2015) 1–11the protein and RNA content of endothelial cell-derived exosomes, J. Extracell.
Vesicles 1 (2012) 18396.
[47] J.E. Park, H.S. Tan, A. Datta, R.C. Lai, H. Zhang, W. Meng, S.K. Lim, S.K. Sze, Hypoxic
tumor cell modulates its microenvironment to enhance angiogenic and metastatic
potential by secretion of proteins and exosomes, Mol. Cell. Proteomics 9 (2010)
1085–1099.
[48] X. Zhang, X. Wang, H. Zhu, E.G. Kranias, Y. Tang, T. Peng, J. Chang, G.C. Fan, Hsp20
functions as a novel cardiokine in promoting angiogenesis via activation of
VEGFR2, PLoS One 7 (2012) e32765.
[49] Z.A. Malik, K.S. Kott, A.J. Poe, T. Kuo, L. Chen, K.W. Ferrara, A.A. Knowlton, Cardiac
myocyte exosomes: stability, HSP60, and proteomics, Am. J. Physiol. Heart Circ.
Physiol. 304 (2013) H954–H965.
[50] S. Gupta, A.A. Knowlton, HSP60 trafﬁcking in adult cardiac myocytes: role of the
exosomal pathway, Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H3052–H3056.
[51] M.H. Gambim, O. do Carmo Ade, L. Marti, S. Veríssimo-Filho, L.R. Lopes, M.
Janiszewski, Platelet-derived exosomes induce endothelial cell apoptosis through
peroxynitrite generation: experimental evidence for a novel mechanism of septic
vascular dysfunction, Crit. Care 11 (2007) R107.
[52] Z. Giricz, Z.V. Varga, T. Baranyai, P. Sipos, K. Pálóczi, Á. Kittel, E.I. Buzás, P.
Ferdinandy, Cardioprotection by remote ischemic preconditioning of the rat
heart is mediated by extracellular vesicles, J. Mol. Cell. Cardiol. 68 (2014) 75–78.
[53] Y. Higashijima, H. Sonoda, S. Takahashi, H. Kondo, K. Shigemura, M. Ikeda, Excre-
tion of urinary exosomal AQP2 in rats is regulated by vasopressin and urinary
pH, Am. J. Physiol. Renal. Physiol. 305 (2013) F1412–F1421.
[54] M. Chaineau, L. Danglot, T. Galli, Multiple roles of the vesicular-SNARE TI-VAMP in
post-Golgi and endosomal trafﬁcking, FEBS Lett. 583 (2009) 3817–3826.
[55] C.M. Fader, D.G. Sanchez, M.B.Mestre, M.I. Colombo, TI-VAMP/VAMP7 and VAMP3/
cellubrevin: two v-SNARE proteins involved in speciﬁc steps of the autophagy/
multivesicular body pathways, Biochim. Biophys. Acta 1793 (2009) 1901–1916.
[56] S. Mathivanan, R.J. Simpson, ExoCarta: a compendium of exosomal proteins and
RNA, Proteomics 9 (2009) 4997–5000.
[57] D.K. Kim, et al., EVpedia: an integrated database of high-throughput data for sys-
temic analyses of extracellular vesicles, J. Extracell. Vesicles 2 (2013) (eCollection).
[58] D.S. Choi, D.K. Kim, Y.K. Kim, Y.S. Gho, Proteomics, transcriptomics and lipidomics
of exosomes and ectosomes, Proteomics 13 (2013) 1554–1571.
[59] R.J. Simpson, S.S. Jensen, J.W. Lim, Proteomic proﬁling of exosomes: current per-
spectives, Proteomics 8 (2008) 4083–4099.
[60] G. van Niel, I. Porto-Carreiro, S. Simoes, G. Raposo, Exosomes: a common pathway
for a specialized function, J. Biochem. 140 (2006) 13–21.
[61] B.K. Thakur, et al., Double-stranded DNA in exosomes: a novel biomarker in cancer
detection, Cell Res. 24 (2014) 766–769.
[62] U. Gezer, E. Ozgür, M. Cetinkaya, M. Isin, N. Dalay, Long non-coding RNAs with low
expression levels in cells are enriched in secreted exosomes, Cell Biol. Int. 38
(2014) 1076–1079.
[63] K. Essandoh, G.C. Fan, Role of extracellular and intracellular microRNAs in sepsis,
Biochim. Biophys. Acta 2014 (1842) 2155–2162.
[64] C. Villarroya-Beltri, F. Baixauli, C. Gutiérrez-Vázquez, F. Sánchez-Madrid, M.
Mittelbrunn, Sorting it out: regulation of exosome loading, Semin. Cancer Biol.
(2014), http://dx.doi.org/10.1016/j.semcancer.2014.04.009 (pii: S1044-579X:
00057-1).
[65] H. Valadi, K. Ekström, A. Bossios, M. Sjöstrand, J.J. Lee, J.O. Lötvall, Exosome-
mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic ex-
change between cells, Nat. Cell Biol. 9 (2007) 654–659.
[66] M. Record, C. Subra, S. Silvente-Poirot, M. Poirot, Exosomes as intercellular
signalosomes and pharmacological effectors, Biochem. Pharmacol. 81 (2011)
1171–1182.
[67] X.Wang,W. Huang, G. Liu, W. Cai, R.W. Millard, Y.Wang, J. Chang, T. Peng, G.C. Fan,
Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the
exosomal transfer of miR-320 into endothelial cells, J. Mol. Cell. Cardiol. 74
(2014) 139–150.
[68] C. Bang, et al., Cardiac ﬁbroblast-derived microRNA passenger strand-enriched
exosomes mediate cardiomyocyte hypertrophy, J. Clin. Invest. 124 (2014)
2136–2146.
[69] J. Halkein, et al., MicroRNA-146a is a therapeutic target and biomarker for peripar-
tum cardiomyopathy, J. Clin. Invest. 123 (2013) 2143–2154.
[70] G. Turturici, R. Tinnirello, G. Sconzo, F. Geraci, Extracellular membrane vesicles as a
mechanism of cell-to-cell communication: advantages and disadvantages, Am. J.
Physiol. Cell Physiol. 306 (2014) C621–C633.
[71] T. Oka, I. Komuro, Molecular mechanisms underlying the transition of cardiac hy-
pertrophy to heart failure, Circ. J. 72 (Suppl. A) (2008) A13–A16.
[72] G.C. Fan, E.G. Kranias, Small heat shock protein 20 (HspB6) in cardiac hypertrophy
and failure, J. Mol. Cell. Cardiol. 51 (2011) 574–577.
[73] D.V. Abramochkin, I.T. Lozinsky, A. Kamkin, Inﬂuence ofmechanical stress on ﬁbro-
blast–myocyte interactions in mammalian heart, J. Mol. Cell. Cardiol. 70 (2014)
27–36.
[74] W. Chen, N.G. Frangogiannis, Fibroblasts in post-infarction inﬂammation and car-
diac repair, Biochim. Biophys. Acta 2013 (1833) 945–953.
[75] M.J. van Amerongen, F.B. Engel, Features of cardiomyocyte proliferation and its po-
tential for cardiac regeneration, J. Cell. Mol. Med. 12 (2008) 2233–2244.
[76] E.M. Zeisberg, R. Kalluri, Origins of cardiac ﬁbroblasts, Circ. Res. 107 (2010)
1304–1312.
[77] S. Fredj, J. Bescond, C. Louault, D. Potreau, Interactions between cardiac cells en-
hance cardiomyocyte hypertrophy and increase ﬁbroblast proliferation, J. Cell.
Physiol. 202 (2005) 891–899.
[78] W.A. LaFramboise, et al., Cardiac ﬁbroblasts inﬂuence cardiomyocyte phenotype
in vitro, Am. J. Physiol. Cell Physiol. 292 (2007) C1799–C1808.[79] A.M. Queirós, C. Eschen, D. Fliegner, G. Kararigas, E. Dworatzek, C. Westphal, H.
Sanchez Ruderisch, V. Regitz-Zagrosek, Sex- and estrogen-dependent regulation
of a miRNA network in the healthy and hypertrophied heart, Int. J. Cardiol. 169
(2013) 331–338.
[80] D. Hilﬁker-Kleiner, K. Sliwa, H. Drexler, Peripartum cardiomyopathy: recent in-
sights in its pathophysiology, Trends Cardiovasc. Med. 18 (2008) 173–179.
[81] J. Li, S. Umar, M. Amjedi, A. Iorga, S. Sharma, R.D. Nadadur, V. Regitz-Zagrosek, M.
Eghbali, New frontiers in heart hypertrophy during pregnancy, Am. J. Cardiovasc.
Dis. 2 (2012) 192–207.
[82] D. Hilﬁker-Kleiner, et al., A cathepsin D-cleaved 16 kDa form of prolactin mediates
postpartum cardiomyopathy, Cell 128 (2007) 589–600.
[83] J.A. Antonelli, N.M. Maalouf, M.S. Pearle, Y. Lotan, Use of the National Health and
Nutrition Examination Survey to calculate the impact of obesity and diabetes on
cost and prevalence of urolithiasis in 2030, Eur. Urol. (2014), http://dx.doi.org/
10.1016/j.eururo.2014.06.036 (pii: S0302-2838(14)00610-1).
[84] K. Raslova, An update on the treatment of type 1 and type 2 diabetes mellitus:
focus on insulin detemir, a long-acting human insulin analog, Vasc. Health Risk
Manag. 6 (2010) 399–410.
[85] H. Nakagami, Y. Kaneda, T. Ogihara, R. Morishita, Endothelial dysfunction in hyper-
glycemia as a trigger of atherosclerosis, Curr. Diabetes Rev. 1 (2005) 59–63.
[86] G. Cohen, Y. Riahi, E. Alpert, A. Gruzman, S. Sasson, The roles of hyperglycaemia
and oxidative stress in the rise and collapse of the natural protective mechanism
against vascular endothelial cell dysfunction in diabetes, Arch. Physiol. Biochem.
113 (2007) 259–267.
[87] Z.V. Varga, Z. Giricz, L. Liaudet, G. Haskó, P. Ferdinandy, P. Pacher, Interplay of ox-
idative, nitrosative/nitrative stress, inﬂammation, cell death and autophagy in dia-
betic cardiomyopathy, Biochim. Biophys. Acta (2014), http://dx.doi.org/10.1016/j.
bbadis.2014.06.030 (pii:S0925-4439(14)00207-5).
[88] P.C. Hsieh, M.E. Davis, L.K. Lisowski, R.T. Lee, Endothelial–cardiomyocyte interac-
tions in cardiac development and repair, Annu. Rev. Physiol. 68 (2006) 51–66.
[89] A. Waldenström, N. Gennebäck, U. Hellman, G. Ronquist, Cardiomyocyte
microvesicles contain DNA/RNA and convey biological messages to target cells,
PLoS One 7 (2012) e34653.
[90] K.N. Iskander, M.F. Osuchowski, D.J. Stearns-Kurosawa, S. Kurosawa, D. Stepien, C.
Valentine, D.G. Remick, Sepsis: multiple abnormalities, heterogeneous responses,
and evolving understanding, Physiol. Rev. 93 (2013) 1247–1288.
[91] F.J. Romero-Bermejo, M. Ruiz-Bailen, J. Gil-Cebrian, M.J. Huertos-Ranchal, Sepsis-
induced cardiomyopathy, Curr. Cardiol. Rev. 7 (2011) 163–183.
[92] L.C. Azevedo, M. Janiszewski, V. Pontieri, A. Pedro Mde, E. Bassi, P.J. Tucci, F.R.
Laurindo, Platelet-derived exosomes from septic shock patients induce myocardial
dysfunction, Crit. Care 11 (2007) R120.
[93] M. Janiszewski, A.O. Do Carmo, M.A. Pedro, E. Silva, E. Knobel, F.R. Laurindo,
Platelet-derived exosomes of septic individuals possess proapoptotic NAD(P)
H oxidase activity: a novel vascular redox pathway, Crit. Care Med. 32 (2004)
818–825.
[94] H. Wang, P. Zhang, W. Chen, D. Feng, Y. Jia, L. Xie, Serum microRNA signatures
identiﬁed by Solexa sequencing predict sepsis patients' mortality: a prospective
observational study, PLoS One 7 (2012) e38885.
[95] X. Wang, W. Huang, Y. Yang, Y. Wang, T. Peng, J. Chang, C.C. Caldwell, B. Zingarelli,
G.C. Fan, Loss of duplex miR-223 (5p and 3p) aggravates myocardial depression
and mortality in polymicrobial sepsis, Biochim. Biophys. Acta 2014 (1842)
701–711.
[96] F. Taïbi, V. Metzinger-Le Meuth, Z.A. Massy, L. Metzinger, miR-223: an inﬂammato-
ry oncomiR enters the cardiovascular ﬁeld, Biochim. Biophys. Acta 1842 (2014)
1001–1009.
[97] F. Tabet, et al., HDL-transferred microRNA-223 regulates ICAM-1 expression in en-
dothelial cells, Nat. Commun. 5 (2014) 3292.
[98] F. van den Akker, J.C. Deddens, P.A. Doevendans, J.P. Sluijter, Cardiac stem cell ther-
apy to modulate inﬂammation upon myocardial infarction, Biochim. Biophys. Acta
2013 (1830) 2449–2458.
[99] R.M. Kanashiro-Takeuchi, I.H. Schulman, J.M. Hare, Pharmacologic and genetic
strategies to enhance cell therapy for cardiac regeneration, J. Mol. Cell. Cardiol.
51 (2011) 619–625.
[100] O. Iglesias-García, B. Pelacho, F. Prósper, Induced pluripotent stem cells as a new
strategy for cardiac regeneration and disease modeling, J. Mol. Cell. Cardiol. 62
(2013) 43–50.
[101] M. Makridakis, M.G. Roubelakis, A. Vlahou, Stem cells: insights into the secretome,
Biochim. Biophys. Acta 2013 (1834) 2380–2384.
[102] R.C. Lai, et al., Exosome secreted by MSC reduces myocardial ischemia/reperfusion
injury, Stem Cell Res. 4 (2010) 214–222.
[103] F. Arslan, et al., Mesenchymal stem cell-derived exosomes increase ATP levels, de-
crease oxidative stress and activate PI3K/Akt pathway to enhance myocardial via-
bility and prevent adverse remodeling after myocardial ischemia/reperfusion
injury, Stem Cell Res. 10 (2013) 301–312.
[104] C. Lee, S.A. Mitsialis, M. Aslam, S.H. Vitali, E. Vergadi, G. Konstantinou, K. Sdrimas, A.
Fernandez-Gonzalez, S. Kourembanas, Exosomes mediate the cytoprotective ac-
tion of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension,
Circulation 126 (2012) 2601–2611.
[105] R. Burt, W. Pearce, K. Luo, Y. Oyama, C. Davidson, N. Beohar, M. Gheorghiade, He-
matopoietic stem cell transplantation for cardiac and peripheral vascular disease,
Bone Marrow Transplant. 32 (Suppl. 1) (2003) S29–S31.
[106] K. Fukuda, J. Fujita, Mesenchymal, but not hematopoietic, stem cells can be mobi-
lized and differentiate into cardiomyocytes after myocardial infarction in mice,
Kidney Int. 68 (2005) 1940–1943.
[107] L.B. Balsam, R.C. Robbins, Haematopoietic stem cells and repair of the ischaemic
heart, Clin. Sci. (Lond.) 109 (2005) 483–492.
11S. Ailawadi et al. / Biochimica et Biophysica Acta 1852 (2015) 1–11[108] C.E. Murry, H. Reinecke, L.M. Pabon, Regeneration gaps: observations on stem cells
and cardiac repair, J. Am. Coll. Cardiol. 47 (2006) 1777–1785.
[109] P. Anversa, A. Leri, M. Rota, T. Hosoda, C. Bearzi, K. Urbanek, J. Kajstura, R. Bolli, Con-
cise review: stem cells, myocardial regeneration, and methodological artifacts,
Stem Cells 25 (2007) 589–601.
[110] G.M. Balmer, P.R. Riley, Harnessing the potential of adult cardiac stem cells: lessons
from haematopoiesis, the embryo and the niche, J. Cardiovasc. Transl. Res. 5 (2012)
631–640.
[111] S. Sahoo, et al., Exosomes from human CD34(+) stem cells mediate their
proangiogenic paracrine activity, Circ. Res. 109 (2011) 724–728.
[112] T.S. Li, M. Kubo, K. Ueda, M.Murakami, A. Mikamo, K. Hamano, Impaired angiogen-
ic potency of bone marrow cells from patients with advanced age, anemia, and
renal failure, J. Thorac. Cardiovasc. Surg. 139 (2010) 459–465.
[113] R. Madonna, F.V. Renna, C. Cellini, R. Cotellese, N. Picardi, F. Francomano, P.
Innocenti, R. De Caterina, Age-dependent impairment of number and angiogenic
potential of adipose tissue-derived progenitor cells, Eur. J. Clin. Invest. 41 (2011)
126–133.
[114] A.R. Mackie, et al., Sonic hedgehog-modiﬁed human CD34+ cells preserve cardiac
function after acute myocardial infarction, Circ. Res. 111 (2012) 312–321.
[115] K.R. Vrijsen, J.P. Sluijter, M.W. Schuchardt, B.W. van Balkom, W.A. Noort, S.A.
Chamuleau, P.A. Doevendans, Cardiomyocyte progenitor cell-derived exosomes
stimulate migration of endothelial cells, J. Cell. Mol. Med. 14 (2010) 1064–1070.
[116] L. Chen, Y.Wang, Y. Pan, L. Zhang, C. Shen, G. Qin,M. Ashraf, N.Weintraub, G.Ma, Y.
Tang, Cardiac progenitor-derived exosomes protect ischemic myocardium from
acute ischemia/reperfusion injury, Biochem. Biophys. Res. Commun. 431 (2013)
566–571.
[117] X. Zhang, X.Wang, H. Zhu, C. Zhu, Y.Wang,W.T. Pu, A.G. Jegga, G.C. Fan, Synergistic
effects of the GATA-4-mediatedmiR-144/451 cluster in protection against simulat-
ed ischemia/reperfusion-induced cardiomyocyte death, J. Mol. Cell. Cardiol. 49
(2010) 841–850.
[118] R.R. Smith, L. Barile, H.C. Cho, M.K. Leppo, J.M. Hare, E. Messina, A. Giacomello, M.R.
Abraham, E. Marbán, Regenerative potential of cardiosphere-derived cells expand-
ed from percutaneous endomyocardial biopsy specimens, Circulation 115 (2007)
896–908.
[119] D.R. Davis, Y. Zhang, R.R. Smith, K. Cheng, J. Terrovitis, K. Malliaras, T.S. Li, A. White,
R. Makkar, E. Marbán, Validation of the cardiosphere method to culture cardiac
progenitor cells from myocardial tissue, PLoS One 4 (2009) e7195.
[120] M. Machida, Y. Takagaki, R. Matsuoka, N. Kawaguchi, Proteomic comparison of
spherical aggregates and adherent cells of cardiac stem cells, Int. J. Cardiol. 153
(2011) 296–305.
[121] I. Chimenti, R. Gaetani, L. Barile, E. Forte, V. Ionta, F. Angelini, G. Frati, E. Messina, A.
Giacomello, Isolation and expansion of adult cardiac stem/progenitor cells in theform of cardiospheres from human cardiac biopsies and murine hearts, Methods
Mol. Biol. 879 (2012) 327–338.
[122] K. Cheng, et al., Human cardiosphere-derived cells from advanced heart failure pa-
tients exhibit augmented functional potency in myocardial repair, JACC Heart Fail.
2 (2014) 49–61.
[123] V. Sousonis, J. Nanas, J. Terrovitis, Cardiosphere-derived progenitor cells for myo-
cardial repair following myocardial infarction, Curr. Pharm. Des. 20 (2014)
2003–2011.
[124] M. Kreke, R.R. Smith, L. Marbán, E. Marbán, Cardiospheres and cardiosphere-
derived cells as therapeutic agents following myocardial infarction, Expert. Rev.
Cardiovasc. Ther. 10 (2012) 1185–1194.
[125] A.G. Ibrahim, K. Cheng, E. Marbán, Exosomes as critical agents of cardiac regener-
ation triggered by cell therapy, Stem Cell Rep. 2 (2014) 606–619.
[126] S. Sanada, I. Komuro, M. Kitakaze, Pathophysiology of myocardial reperfusion inju-
ry: preconditioning, postconditioning, and translational aspects of protective mea-
sures, Am. J. Physiol. Heart Circ. Physiol. 301 (2011) H1723–H1741.
[127] X. Wang, H. Zhu, X. Zhang, Y. Liu, J. Chen, M. Medvedovic, H. Li, M.J. Weiss, X.
Ren, G.C. Fan, Loss of the miR-144/451 cluster impairs ischaemic
preconditioning-mediated cardioprotection by targeting Rac-1, Cardiovasc.
Res. 94 (2012) 379–390.
[128] J. Li, S. Rohailla, N. Gelber, J. Rutka, N. Sabah, R.A. Gladstone, C. Wei, P. Hu, R.K.
Kharbanda, A.N. Redington,MicroRNA-144 is a circulating effector of remote ische-
mic preconditioning, Basic Res. Cardiol. 109 (2014) 423.
[129] J. Jeanneteau, P. Hibert, M.C. Martinez, S. Tual-Chalot, S. Tamareille, A. Furber,
R. Andriantsitohaina, F. Prunier, Microparticle release in remote ischemic
conditioning mechanism, Am. J. Physiol. Heart Circ. Physiol. 303 (2012)
H871–H877.
[130] Y. Feng, W. Huang, M.Wani, X. Yu, M. Ashraf, Ischemic preconditioning potentiates
the protective effect of stem cells through secretion of exosomes by targeting
Mecp2 via miR-22, PLoS One 9 (2014) e88685.
[131] A. Yuan, E.L. Farber, A.L. Rapoport, D. Tejada, R. Deniskin, N.B. Akhmedov, D.B.
Farber, Transfer of microRNAs by embryonic stem cell microvesicles, PLoS One 4
(2009) e4722.
[132] A. Curcio, et al., MicroRNA-1 downregulation increases connexin 43 displacement
and induces ventricular tachyarrhythmias in rodent hypertrophic hearts, PLoS One
8 (2013) e70158.
[133] C. Indolﬁ, A. Curcio, Stargazing microRNA maps a new miR-21 star for cardiac hy-
pertrophy, J. Clin. Invest. 124 (2014) 1896–1898.
[134] L. Barile, V. Lionetti, E. Cervio, M. Matteucci, M. Gherghiceanu, L.M. Popescu, T.
Torre, F. Siclari, T. Moccetti, G. Vassalli, Extracellular vesicles from human cardiac
progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function
after myocardial infarction, Cardiovasc. Res. 103 (2014) 530–541.
